Results 11 to 20 of about 1,580 (184)
Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy
BiomedicinesHypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease, with an estimated prevalence of 1:600 in the general population, and is associated with significant morbidity.
Helin Savsin, Tomasz Tokarek
doaj +4 more sources
Drugs, 2022 Mavacamten (Camzyos™) is an oral small-molecule cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of diastolic dysfunction. In April 2022, mavacamten was approved for use in the USA in the treatment of adults with symptomatic New ...
Susan Keam (4873372)
openaire +3 more sources
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy [PDF]
New England Journal of MedicineMavacamten is approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, its effects in nonobstructive HCM remain uncertain.We conducted a phase 3, international, double-blind, placebo-controlled, clinical trial to determine whether mavacamten improves functional capacity and patient-reported health status among ...
Desai Milind Y +29 more
core +7 more sources
The Egyptian Heart Journal, 2023 Background Hypertrophic cardiomyopathy (HCM) is a hereditary myocardial disorder, often due to sarcomere gene mutations, characterized by the left ventricular hypertrophy. Current treatments offer symptomatic relief but lack specificity.
Hussain Sohail Rangwala +5 more
doaj +2 more sources
MAVACAMTEN NO TRATAMENTO DA CARDIOMIOPATIA HIPERTRÓFICA
RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218, 2023 Introdução: A cardiomiopatia hipertrófica (CMH) é uma das doenças cardíacas genéticas mais comuns, afetando entre 0,16% e 0,29% da população adulta geral. É uma doença genética do miocárdio e caracteriza-se por acentuada hipertrofia miocárdica que não pode ser explicada pela carga pressórica ou pela presença de desarranjo miocitário.
Caique Pereira de Paiva +9 more
openaire +3 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.
Ingy Mahana +7 more
doaj +2 more sources
The Egyptian Heart Journal, 2023 Background Mavacamten, an allosteric myosin inhibitor, is considered to be a promising drug for the treatment of hypertrophic cardiomyopathy (HCM). This meta-analysis aimed to explore the safety and efficacy of mavacamten in HCM patients.
Mehrdad Rabiee Rad +2 more
doaj +2 more sources
Clinical and Translational ScienceObstructive hypertrophic cardiomyopathy (oHCM) is a subtype of HCM characterized by left ventricular outflow tract obstruction resulting from cardiac muscle hypertrophy and anatomic alterations in the mitral valve and apparatus.
Xiaojie Wu +18 more
doaj +2 more sources
Cardiology and TherapyIntroduction Mavacamten, a cardiac myosin inhibitor, has demonstrated positive outcomes in left ventricular outflow tract (LVOT) gradient reduction and improvements of symptoms and function in Chinese patients with symptomatic obstructive hypertrophic ...
Zhuang Tian +16 more
doaj +2 more sources
Future Science OA, 2023 Aim: This meta-analysis was performed to assess the efficacy and safety of mavacamten in patients with hypertrophic cardiomyopathy. Methods & materials: A search was conducted using PubMed, Cochrane, and Scopus up to August 2022 for randomized studies ...
Areeba Memon +9 more
doaj +2 more sources